TrialJNCI cancer spectrum2023

Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3.

Kei Kawana et al.PubMed ↗Publisher ↗

No numbers read from the abstract.